Idursulfase: enzyme replacement therapy for mucopolysaccharidosis Type II (Hunter syndrome)

References

• Barton NW, Brady RO, Dambrosia JM et al. Replacement therapy for inherited enzyme deficiency – macrophage-targeted glucocerebrosidase for Gaucher’s disease. N. Engl. J. Med.324(21), 1464–1470 (1991).
   PubMed Web of Science ®Google Scholar
• Barton NW, Furbish FS, Murray GJ, Garfield M, Brady RO. Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease. Proc. Natl Acad. Sci. USA87(5), 1913–1916 (1990).
   PubMed Web of Science ®Google Scholar
• Brady RO, Pentchev PG, Gal AE, Hibbert SR, Dekaban AS. Replacement therapy for inherited enzyme deficiency. Use of purified glucocerebrosidase in Gaucher’s disease. N. Engl. J. Med.291(19), 989–993 (1974).
   PubMed Web of Science ®Google Scholar
• Brady RO, Tallman JF, Johnson WG et al. Replacement therapy for inherited enzyme deficiency. Use of purified ceramidetrihexosidase in Fabry’s disease. N. Engl. J. Med.289(1), 9–14 (1973).
   PubMed Web of Science ®Google Scholar
• Grabowski GA, Barton NW, Pastores G et al. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann. Intern. Med.122(1), 33–39 (1995).
   PubMed Web of Science ®Google Scholar
• Scriver CR. The Metabolic and Molecular Bases of Inherited Disease. McGraw-Hill, NY, USA (2001).
   Google Scholar
• Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA281(3), 249–254 (1999).
   PubMed Web of Science ®Google Scholar
• Tuschl K, Gal A, Paschke E, Kircher S, Bodamer OA. Mucopolysaccharidosis type II in females: case report and review of literature. Pediatr. Neurol.32(4), 270–272 (2005).
   PubMed Web of Science ®Google Scholar
• Young ID, Harper PS. The natural history of the severe form of Hunter’s syndrome: a study based on 52 cases. Dev. Med. Child Neurol.25(4), 481–489 (1983).
   PubMed Web of Science ®Google Scholar
• Young ID, Harper PS. Mild form of Hunter’s syndrome: clinical delineation based on 31 cases. Arch. Dis. Child.57(11), 828–836 (1982).
   PubMed Web of Science ®Google Scholar
• Barton RW, Neufeld EF. The Hurler corrective factor. Purification and some properties. J. Biol. Chem.246(24), 7773–7779 (1971).
   PubMed Web of Science ®Google Scholar
• Hickman S, Neufeld EF. A hypothesis for I-cell disease: defective hydrolases that do not enter lysosomes. Biochem. Biophys. Res. Commun.49(4), 992–999 (1972).
   PubMed Web of Science ®Google Scholar
• Sahagian GG, Distler J, Jourdian GW. Characterization of a membrane-associated receptor from bovine liver that binds phosphomannosyl residues of bovine testicular β-galactosidase. Proc. Natl Acad. Sci. USA78(7), 4289–4293 (1981).
   PubMed Web of Science ®Google Scholar
• Wilson PJ, Morris CP, Anson DS et al. Hunter syndrome: isolation of an iduronate-2-sulfatase cDNA clone and analysis of patient DNA. Proc. Natl Acad. Sci. USA87(21), 8531–8535 (1990).
   PubMed Web of Science ®Google Scholar
• Hopwood JJ, Bunge S, Morris CP et al. Molecular basis of mucopolysaccharidosis type II: mutations in the iduronate-2-sulphatase gene. Hum. Mutat.2(6), 435–442 (1993).
   PubMed Web of Science ®Google Scholar
• Froissart R, Maire I, Millat G et al. Identification of iduronate sulfatase gene alterations in 70 unrelated Hunter patients. Clin. Genet.53(5), 362–368 (1998).
   PubMed Web of Science ®Google Scholar
• de Jong JG, Hasselman JJ, van Landeghem AA, Vader HL, Wevers RA. The spot test is not a reliable screening procedure for mucopolysaccharidoses. Clin. Chem.37(4), 572–575 (1991).
   PubMed Web of Science ®Google Scholar
• Mabe P, Valiente A, Soto V, Cornejo V, Raimann E. Evaluation of reliability for urine mucopolysaccharidosis screening by dimethylmethylene blue and Berry spot tests. Clin. Chim. Acta345(1–2), 135–140 (2004).
   PubMed Web of Science ®Google Scholar
• Parkinson EJ, Muller V, Hopwood JJ, Brooks DA. Iduronate-2-sulphatase protein detection in plasma from mucopolysaccharidosis type II patients. Mol. Genet. Metab.81(1), 58–64 (2004).
   PubMed Web of Science ®Google Scholar
• Voznyi YV, Keulemans JL, van Diggelen OP. A fluorimetric enzyme assay for the diagnosis of MPS II (Hunter disease). J. Inherit. Metab. Dis.24(6), 675–680 (2001).
   PubMed Web of Science ®Google Scholar
• Filocamo M, Bonuccelli G, Corsolini F et al. Molecular analysis of 40 Italian patients with mucopolysaccharidosis type II: new mutations in the iduronate-2-sulfatase (IDS) gene. Hum. Mutat.18(2), 164–165 (2001).
   PubMedGoogle Scholar
• Li P, Bellows AB, Thompson JN. Molecular basis of iduronate-2-sulphatase gene mutations in patients with mucopolysaccharidosis type II (Hunter syndrome). J. Med. Genet.36(1), 21–27 (1999).
   PubMed Web of Science ®Google Scholar
• Vafiadaki E, Cooper A, Heptinstall LE et al. Mutation analysis in 57 unrelated patients with MPS II (Hunter’s disease). Arch. Dis. Child.79(3), 237–241 (1998).
   PubMed Web of Science ®Google Scholar
• Krivit W, Peters C, Shapiro EG. Bone marrow transplantation as effective treatment of central nervous system disease in globoid cell leukodystrophy, metachromatic leukodystrophy, adrenoleukodystrophy, mannosidosis, fucosidosis, aspartylglucosaminuria, Hurler, Maroteaux-Lamy, and Sly syndromes, and Gaucher disease type III. Curr. Opin. Neurol.12(2), 167–176 (1999).
   PubMed Web of Science ®Google Scholar
• Souillet G, Guffon N, Maire I et al. Outcome of 27 patients with Hurler’s syndrome transplanted from either related or unrelated haematopoietic stem cell sources. Bone Marrow Transplant.31(12), 1105–1117 (2003).
   PubMed Web of Science ®Google Scholar
• Peters C, Krivit W. Hematopoietic cell transplantation for mucopolysaccharidosis IIB (Hunter syndrome). Bone Marrow Transplant.25(10), 1097–1099 (2000).
   PubMed Web of Science ®Google Scholar
• Peters C, Steward CG. Hematopoietic cell transplantation for inherited metabolic diseases: an overview of outcomes and practice guidelines. Bone Marrow Transplant.31(4), 229–239 (2003).
   PubMed Web of Science ®Google Scholar
• Baehner F, Schmiedeskamp C, Krummenauer F et al. Cumulative incidence rates of the mucopolysaccharidoses in Germany. J. Inherit. Metab. Dis.28(6), 1011–1017 (2005).
   PubMed Web of Science ®Google Scholar
• Muenzer J, Lamsa JC, Garcia A et al. Enzyme replacement therapy in mucopolysaccharidosis type II (Hunter syndrome): a preliminary report. Acta Paediatr. Suppl.91(439), 98–99 (2002).
   PubMedGoogle Scholar
• Muenzer J, Wraith JE, Beck M et al. A Phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet. Med.8(8), 465–473 (2006).
   PubMed Web of Science ®Google Scholar
• Harmatz P, Giugliani R, Schwartz I et al. Enzyme replacement therapy for mucopolysaccharidosis VI: a Phase III, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J. Pediatr.148(4), 533–539 (2006).
   PubMed Web of Science ®Google Scholar
• Wraith JE. The first 5 years of clinical experience with laronidase enzyme replacement therapy for mucopolysaccharidosis I. Expert Opin. Pharmacother.6(3), 489–506 (2005).
   PubMed Web of Science ®Google Scholar
• Wraith JE, Clarke LA, Beck M et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human α-L-iduronidase (laronidase). J. Pediatr.144(5), 581–588 (2004).
   PubMed Web of Science ®Google Scholar
• Aviner S, Levy Y, Yaniv I, Cohen IJ. Anaphylactoid reaction to imiglucerase, but not to alglucerase, in a type I Gaucher patient. Blood Cells Mol. Dis.25(2), 92–94 (1999).
   PubMedGoogle Scholar
• Eng CM, Guffon N, Wilcox WR et al. Safety and efficacy of recombinant human α-galactosidase A – replacement therapy in Fabry’s disease. N. Engl. J. Med.,345(1), 9–16 (2001).
   PubMed Web of Science ®Google Scholar
• Wilcox WR, Banikazemi M, Guffon N et al. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am. J. Hum. Genet.75(1), 65–74 (2004).
   PubMed Web of Science ®Google Scholar
• ATS statement: guidelines for the six-minute walk test. Am. J. Respir. Crit. Care Med.166(1), 111–117 (2002).
   PubMed Web of Science ®Google Scholar
• von Specht BU, Geiger B, Arnon R et al. Enzyme replacement in Tay-Sachs disease. Neurology29(6), 848–854 (1979).
   PubMed Web of Science ®Google Scholar
• Kakkis E, McEntee M, Vogler C et al. Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I. Mol. Genet. Metab.83(1–2), 163–174 (2004).
   PubMed Web of Science ®Google Scholar
• Roces DP, Lullmann-Rauch R, Peng J et al. Efficacy of enzyme replacement therapy in α-mannosidosis mice: a preclinical animal study. Hum. Mol. Genet.13(18), 1979–1988 (2004).
   PubMed Web of Science ®Google Scholar
• Vogler C, Levy B, Grubb JH et al. Overcoming the blood–brain–barrier with high-dose enzyme replacement therapy in murine mucopolysaccharidosis VII. Proc. Natl Acad. Sci. USA102(41), 14777–14782 (2005).
   PubMed Web of Science ®Google Scholar
• Desnick RJ. Enzyme replacement and enhancement therapies for lysosomal diseases. J. Inherit. Metab. Dis.27(3), 385–410 (2004).
   PubMed Web of Science ®Google Scholar
• Cox TM. Substrate reduction therapy for lysosomal storage diseases. Acta Paediatr. Suppl.94(447), 69–75; discussion 57 (2005).
   PubMedGoogle Scholar
• Cardone M, Polito VA, Pepe S et al. Correction of Hunter syndrome in the MPSII mouse model by AAV2/8-mediated gene delivery. Hum. Mol. Genet.15(7), 1225–1236 (2006).
   PubMed Web of Science ®Google Scholar
• Friso A, Tomanin R, Alba S et al. Reduction of GAG storage in MPS II mouse model following implantation of encapsulated recombinant myoblasts. J. Gene Med.7(11), 1482–1491 (2005).
   PubMed Web of Science ®Google Scholar